Evaluate the Efficacy and Safety of MEDITOXIN in Treatment of Primary Axillary Hyperhidrosis

Medy-Tox220 enrolled

Overview

This study is intented to evaluate the efficacy and safety of MEDITOXIN compared to placebo in treatment of primary axillary hyperhidrosis.

Study Type

INTERVENTIONAL

Allocation

RANDOMIZED

Purpose

TREATMENT

Masking

QUADRUPLE

Enrollment

220

Conditions

Hyperhidrosis Primary Focal Axilla

Interventions

MeditoxinDRUG

50U of MEDITOXIN is injected intradermally to each axilla

PlaceboOTHER

normal saline is injected intradermally to each axilla

Eligibility

Sex: ALLMin age: 20 YearsMax age: 65 Years

Medical Language ↔ Plain English

Inclusion Criteria: * adult patients aged from 20 to 65, with persistent bilateral primary axillary hyperhidrosis Exclusion Criteria: * those who have secondary hyperhidrosis * those who have systemic neuromuscular junction disorders * women who are pregnant or lactating

Locations (1)

Catholic University St. Paul Hospital

Seoul, Dongdaemun-gu, South Korea

Outcomes

Primary Outcomes

the proportion of treatment responder

subjects who reported at least a 2-point improvement from baseline HDSS score

Time frame: 4 weeks after the injection

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.